BDC 3042
Alternative Names: BDC-3042Latest Information Update: 17 Jan 2024
At a glance
- Originator Bolt Biotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 16 Oct 2023 Bolt Biotherapeutics plans a phase I trial for BDC 3042 in the second half of 2023
- 25 Sep 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06052852)
- 25 Sep 2023 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Monotherapy, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) (NCT06052852)